Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Metronomic chemotherapy for head and neck cancer

Rushabh Kiran Kothari, MD, Narayana Multispeciality Hospital, Ahmedabad, India, explains how second-line treatments for head and neck cancer have dissimilar outcomes to chemotherapy, with immunotherapy being the treatment of choice. A statistically significant improvement in overall -survival (OS) and response rates is seen when patients are treated with nivolumab and pembrolizumab. Phase III trials have shown the efficacy of oral metronomic chemotherapy and triple metronomic chemotherapy. This data led to the recruitment of patients with head and neck cancer for the CRSF 2021-HN-001 trial. These patients were platinum refractory or scheduled to undergo second-line treatment. Patients were randomized to metronomic chemotherapy or physician’s choice of treatment (chemotherapy, targeted therapy, or immunotherapy). The primary end point was OS and the second endpoints were progression free survival (PFS), quality of life and adverse events (AEs). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.